dacomitinib

12/01/2014 - "Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial."
04/01/2019 - "On September 27, 2018, the United States Food and Drug Administration (FDA) approved dacomitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations. "
05/01/2022 - "Efficacy of dacomitinib in patients with non-small cell lung cancer carrying complex EGFR mutations: a real-world study."
01/01/2021 - "Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050)."
04/01/2014 - "Further clinical trials are underway to evaluate the efficacy of dacomitinib in non-small-cell lung cancer. "

04/22/2010 - "Irreversible EGFR inhibitors, including PF00299804, are effective in vitro and in vivo against EGFR mutant tumors that contain EGFR T790M and are currently under clinical development. "
10/17/2022 - "A landmark publication in Cancer Research in 2007 demonstrated improved drug potency and pan-human EGFR (HER) inhibition with PF00299804, a second-generation EGFR TKI. "
01/01/2018 - "This study provides a useful combinational therapeutic strategy with dacomitinib and substrates of ABCB1 and/or ABCG2 transporters in ABCB1- or ABCG2-overexpressing cancers."
12/01/2012 - "This phase I, open-label, dose-escalation study (clinicaltrials.gov: NCT00783328) primarily evaluated the safety and tolerability of dacomitinib by dose-limiting toxicity (DLT), and determined the clinically recommended phase II dose (RP2D) in Japanese patients with advanced solid tumors. "
12/05/2023 - "Single-cell transcriptome analysis reveals dynamic changes of the preclinical A549 cancer models, and the mechanism of dacomitinib."

10/01/2017 - "We evaluated safety, pharmacokinetics and efficacy of intermittent pulsatile dacomitinib in both molecularly unselected patients and patients with lung cancers harboring EGFR T790M (Clinical Trial Registration Number NCT01858389). "
10/01/2017 - "Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers."
01/01/2021 - "Dacomitinib-resistant (DR) derivatives of lung cancer cells were established by means of gradually increasing dacomitinib concentrations. "
01/01/2018 - "Our data suggest the importance of analyzing these secondary mutations because appropriate selection of EGFR inhibitors could overcome acquired resistance to dacomitinib in a subset of lung cancers."
07/01/2015 - "Dacomitinib produced objective responses in patients with lung cancers with specific HER2 exon 20 insertions. "

11/27/2023 - "However, because that study did not include patients with brain metastases, the efficacy of dacomitinib in patients with brain metastases has not been clarified. "
12/01/2021 - "Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases."
01/01/2021 - "After initiation of dacomitinib, the neurological symptoms of the patient were remarkably improved and leptomeningeal dissemination and brain metastases were shown to have regressed on magnetic resonance imaging (MRI) scan. "
01/01/2022 - "This real-world study has shown that dacomitinib is active and well-tolerated in NSCLC patients harboring different EGFR mutations in later-line settings, even for those with brain metastases. "
01/01/2018 - "The findings caution against the use of dacomitinib for pediatric brain tumor clinical trials."

01/01/2021 - "Here, we report the efficacy of dacomitinib for uncommon EGFR mutations in a 71-year-old woman diagnosed with metastatic lung adenocarcinoma with uncommon EGFR mutation (Ex18 G719A). "
08/26/2022 - "A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report."
01/01/2022 - "Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases."
01/01/2023 - "Dacomitinib-induced purpuric drug eruptions associated with IQGAP1 upregulation in a patient with lung adenocarcinoma."
12/22/2021 - "We evaluated the effects of fulvestrant and dacomitinib on murine bone marrow-derived macrophages (BMDMs) and CD8+ T cells, and tested the efficacy of the combination in vivo, using the KRAS mutant syngeneic lung adenocarcinoma model, FVBW-17. "